Skip to main content

Table 1 Adapted Newcastle-Ottawa quality assessment

From: Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and rheumatoid arthritis

Study ID S1 S2 S3 S4 C1 C2 E1a E1b E2 E3
Ferrell and colleagues23 * - - - - - - - * -
Lunemann and colleagues24 * - * - * - - - * -
Saal and colleagues25 * - - - * - - * - -
Yazbek and colleagues26 * * - * * * - - * -
Mouzavi-Jazi and colleagues27 - - - * - - - - * -
Blaschke and colleagues28 * - * * * * - - * -
Venables and colleagues 198129 * - - - - - - * * -
Venables and colleagues 198530 * - - * - - - - * -
Sculley and colleagues31 * - * - - - - - * -
Shirodaria and colleagues32 * - - * * * - * * -
Silverman and colleagues33 * - - * * * - - * -
Ng and colleagues34 * - - - - - - - - -
Musiani and colleagues35 * - - * * * - * * -
Yao and colleagues36 * - - - * - - - * -
Philips and colleagues37 * - * * - - - - * -
Nakabayashi and colleagues38 * - - - * * - * - -
Us and colleagues18 * - * * * - - - * *
Youinou and colleagues39 * - * - - - - * * -
Draborg and colleagues40 * - - - - - - * * -
Jorgensen and colleagues41 * * * * * * - * * -
Zhang and colleagues 199919 * - * * - - * * * -
Zhang and colleagues 19936 * - * * - - - - * -
Davies and colleagues42 * - - - * - - - * -
  1. Adapted Newcastle-Ottawa assessment scale. S1 objective case definition used, S2 cases consecutively recruited or obviously representative, S3 community controls, S4 controls specified as having no history of disease, C1 age-matched control, C2 controls matched for additional factor, E1a conducting analysis in a clinical laboratory (away from investigators), E1b explicit laboratory cutoffs for seropositivity mentioned, E2 same method of ascertainment for cases and controls, E3 missing data reported